by | May 17, 2024 | Publications
Nat Commun. 2024 May 16;15(1):4144. doi: 10.1038/s41467-024-48327-9. ABSTRACT Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The malignant...
by | May 17, 2024 | Publications
BMC Nephrol. 2024 May 16;25(1):165. doi: 10.1186/s12882-024-03600-3. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a malignant disorder characterized by monoclonal differentiated plasma cells. While it is more commonly diagnosed in elderly individuals, it can also...
by | May 16, 2024 | Publications
Blood. 2024 May 16;143(20):2015-2016. doi: 10.1182/blood.2024024140. NO ABSTRACT PMID:38753353 | DOI:10.1182/blood.2024024140
by | May 16, 2024 | Publications
World J Oncol. 2024 Jun;15(3):348-354. doi: 10.14740/wjon1780. Epub 2024 Apr 15. ABSTRACT Multiple myeloma (MM), a malignancy involving plasma cells, disproportionately affects older adults with an average age of diagnosis of about 70 years. Oftentimes, the therapies...
by | May 16, 2024 | Publications
Sci Rep. 2024 May 15;14(1):11176. doi: 10.1038/s41598-024-61420-9. ABSTRACT Multiple Myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells within the bone marrow. Diagnosing MM presents considerable challenges, involving...
by | May 16, 2024 | Publications
J Med Chem. 2024 May 15. doi: 10.1021/acs.jmedchem.3c02425. Online ahead of print. ABSTRACT The lack of selective and safe in vivo IRE1α tool molecules has limited the evaluation of IRE1α as a viable target to treat multiple myeloma. Focus on improving the...
